Jeff Ajer compensation by year
BIOMARIN PHARMACEUTICAL Summary Compensation Table · all 8 fiscal years held| Component | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|---|---|---|
| Salary | $490,385 | $524,231 | $554,232 | $580,192 | $628,654 | $610,000 | $638,269 | $669,231 |
| Bonus | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock awards | $2,316,017 | $2,133,048 | $2,146,078 | $4,303,656 | $2,696,310 | $2,941,280 | $3,357,648 | $3,094,233 |
| Option awards | $1,541,900 | $1,439,891 | $1,373,198 | $867,181 | $788,869 | $841,896 | $922,027 | $873,661 |
| Non-equity incentive | $357,750 | $451,560 | $450,240 | $561,600 | $402,600 | $567,300 | $512,775 | $405,000 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $16,361 | $19,572 | $21,635 | $31,693 | $20,003 | $24,933 | $26,619 | $28,232 |
| Total | $4,722,413 | $4,568,302 | $4,545,383 | $6,344,322 | $4,536,436 | $4,985,408 | $5,457,338 | $5,070,357 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: BIOMARIN PHARMACEUTICAL INC DEF 14A filed April 9, 2024, accession 0001048477-24-000058, and prior-year filings. Open the filing on EDGAR.
How this page was built: the BIOMARIN PHARMACEUTICAL INC filed document, accession 0001048477-24-000058. Every figure is read from that document and cited to the page and table it appears in. Filed April 9, 2024.
Equity holdings
unvested awards at FY2023 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| PSU | 11,940 | $1,151,255 | — |
| PSU | 10,720 | $1,033,622 | — |
| PSU | 10,110 | $974,806 | — |
| RSU | 10,110 | $974,806 | — |
| RSU | 8,955 | $863,441 | — |
| PSU | 6,440 | $620,945 | — |
| PSU | 5,970 | $575,627 | — |
| PSU | 5,970 | $575,627 | — |
| RSU | 5,360 | $516,811 | — |
| PSU | 5,060 | $487,885 | — |
| PSU | 5,060 | $487,885 | — |
| PSU | 4,290 | $413,642 | — |
Per the Outstanding Equity Awards at Fiscal Year-End table in BIOMARIN PHARMACEUTICAL INC's FY2023 proxy; value at the fiscal year-end close, as the company printed it. The 12 largest of 17 award rows shown.
BIOMARIN PHARMACEUTICAL’s named executive officers, FY2023
as the company reported each| Named executive officer | Role | FY2023 total |
|---|---|---|
| Jean-Jacques Bienaimé | Former CEO and Former Chairman of the Board | $21,976,020 |
| Alexander Hardy | President and Chief Executive Officer | $17,875,236 |
| Henry Fuchs | President, Worldwide R&D | $9,660,818 |
| C. Greg Guyer | Executive Vice President, Chief Technical Officer | $5,701,119 |
| Jeff Ajer · this page | Executive Vice President, Chief Commercial Officer | $5,070,357 |
| Brian Mueller | Executive Vice President, Finance and CFO | $4,854,192 |
The full BIOMARIN PHARMACEUTICAL compensation record
free company briefThis page is one person within BIOMARIN PHARMACEUTICAL's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the BIOMARIN PHARMACEUTICAL proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are BIOMARIN PHARMACEUTICAL's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.